CLAIMS

1- Solid orodispersible pharmaceutical composition of piribedil, or pharmaceutically acceptable salts thereof, characterised in that it comprises:
- piribedril or a pharmaceutically acceptable salt thereof,
- granules consisting of co-dried lactose and starch.

2- Pharmaceutical composition according to claim 1, characterised in that it comprises, in relation to the total weight of the composition :
- from 5 % to 50 % by weight of piribedil or a pharmaceutically acceptable salt thereof,
- from 50 % to 95 % by weight of granules consisting of co-dried lactose and starch.

3- Pharmaceutical composition according to claim 2, characterised in that it comprises from 10 % to 20 % by weight of piribedil or a pharmaceutically acceptable salt thereof.

4- Pharmaceutical composition according to claim 1, characterised in that it also comprises one or more lubricants and a flow agent.

5- Pharmaceutical composition according to any one of claims 1 to 4, characterised in that it also comprises citric acid.

6- Pharmaceutical composition according to claim 1, characterised in that it is in the form of a tablet.

7- Tablet according to claim 6, characterised in that it is obtained by direct compression.

8- Tablet according to claim 7, characterised in that its hardness is from 15 to 50 Newtons.

9- Tablet according to claim 8, characterised in that its hardness is about 20 Newtons.

10- Use of granules consisting of co-dried lactose and starch in the manufacture of solid orodispersible compositions of piribedil, or pharmaceutically acceptable salts thereof, which disintegrate in the mouth in less than three minutes, preferably less than one minute.

11- Solid orodispersible pharmaceutical composition of piribedil, according to claim 1, for use in the long-term treatment and treatment of acute episodes of Parkinson's disease.